133 related articles for article (PubMed ID: 31423335)
1. Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies.
Osaka I; Ishiki H; Yokota T; Tada Y; Sato H; Okamoto M; Satomi E
ESMO Open; 2019; 4(4):e000527. PubMed ID: 31423335
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Webster LR; Yamada T; Arjona Ferreira JC
Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
Ann Oncol; 2018 Jun; 29(6):1461-1467. PubMed ID: 32151367
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
[TBL] [Abstract][Full Text] [Related]
5. Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives.
Hale ME; Wild JE; Yamada T; Yokota T; Tack J; Andresen V; Drewes AM
Therap Adv Gastroenterol; 2021; 14():17562848211032320. PubMed ID: 34377150
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
Wild J; Webster L; Yamada T; Hale M
Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
[TBL] [Abstract][Full Text] [Related]
7. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy.
Webster LR; Hale ME; Yamada T; Wild JE
J Pain Res; 2020; 13():605-612. PubMed ID: 32280263
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
Esmadi M; Ahmad D; Hewlett A
J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
[TBL] [Abstract][Full Text] [Related]
9. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
[TBL] [Abstract][Full Text] [Related]
10. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
Wild J; Yamada T; Arjona Ferreira JC; Hale M
Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
[TBL] [Abstract][Full Text] [Related]
11. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies.
Saito Y; Yokota T; Arai M; Tada Y; Sumitani M
J Pain Res; 2019; 12():127-138. PubMed ID: 30613161
[TBL] [Abstract][Full Text] [Related]
12. Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients With Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan.
Naya N; Oka H; Hashimoto S; Morioka Y; Kizawa Y
Cureus; 2023 Sep; 15(9):e46090. PubMed ID: 37900431
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.
Kamiya T; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984494
[No Abstract] [Full Text] [Related]
15. Translating Clinical Findings into the Patient's Perspective: Post-hoc Pooled Analysis of Bowel Movement Changes as a Predictor of Improvement in Patients' Opioid-induced Constipation Symptoms and Outcomes.
Coyne KS; Poon JL; Thompson C; Hu Y; Datto CJ; Sostek M
Clin Ther; 2017 Jan; 39(1):75-88. PubMed ID: 27938897
[TBL] [Abstract][Full Text] [Related]
16. Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain.
BouSaba J; Sannaa W; Camilleri M
Therap Adv Gastroenterol; 2022; 15():17562848221078638. PubMed ID: 35509419
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol.
Higashibata T; Hamano J; Kessoku T; Kajiura S; Hirakawa M; Horie Y; Shimizu M; Oyamada S; Ariyoshi K; Kihara K; Yamanaka Y; Konishi K; Doki K; Takashima Y; Horiuchi M; Homma M; Yamada T; Yamamoto Y; Moriwaki T; Morita T; Nakajima A; Nagaoka H
Contemp Clin Trials Commun; 2022 Oct; 29():100967. PubMed ID: 35967517
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients.
Braun UK; Jackson LK; Garcia MA; Imam SN
Pharmacy (Basel); 2024 Mar; 12(2):. PubMed ID: 38525728
[TBL] [Abstract][Full Text] [Related]
19. Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies.
Camilleri M; Hale M; Morlion B; Tack J; Webster L; Wild J
J Pain Res; 2021; 14():2179-2189. PubMed ID: 34295186
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine.
Kubota R; Fukumura K; Wajima T
Pharm Res; 2018 Oct; 35(11):225. PubMed ID: 30280262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
